Article summary
Alignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results…
Continue to the original publication for the complete article.